Investment Rating - The investment rating for WuXi AppTec is "Buy" with a target price of HK$95.00, indicating an expected share price return of 43.2% and an expected total return of 46.0% [5]. Core Insights - WuXi AppTec's CFO maintained the 2025 revenue guidance of Rmb41.5-43.0 billion, reflecting a year-over-year growth of 10-15% for continuing business, with faster bottom line growth than topline [1]. - The company expects TIDES revenue to grow over 60% year-over-year in 2025, with involvement in key GLP-1 projects such as tirzepatide, orforglipron, and retatrutide [2]. - WuXi AppTec currently has the world's largest peptide capacity of 41,000L, aiming to expand to 100,000L by the end of 2025 [2]. - The Testing and Biology businesses are anticipated to recover in the second half of 2025, with management noting that over 50% of Testing revenue comes from Chinese clients [3]. - The CDMO business is viewed as a cornerstone, with over 90% retention of projects in the Chemistry business for Phase 2/3/CMO projects [4]. Summary by Sections Financial Performance - Revenue guidance for 2025 is set at Rmb41.5-43.0 billion, with a projected growth rate of 10-15% year-over-year for continuing business [1]. - The expected share price return is 43.2%, with a total expected return of 46.0% [5]. Business Segments - TIDES revenue is expected to grow over 60% year-over-year in 2025, with significant involvement in GLP-1 projects [2]. - The company is confident in adding approximately 10 commercial projects to its pipeline annually [4]. - The Testing and Biology segments are expected to show double-digit growth in volume, with a recovery anticipated in the second half of 2025 [3]. Capacity and Expansion - WuXi AppTec currently operates with a peptide capacity of 41,000L, the largest globally, and aims to increase this to 100,000L by the end of 2025 [2]. - The company retains over 90% of projects in the Chemistry business for Phase 2/3/CMO projects, indicating strong project management capabilities [4].
花旗:药明生物- 有望成为 GLP - 1 项目的主要受益方